Physicians' Academy for Cardiovascular Education

DOACs and warfarin beneficial for older AF patients according to FORTA classification

Appropriateness of Oral Anticoagulants for the Long-Term Treatment of Atrial Fibrillation in Older People: Results of an Evidence-Based Review and International Consensus Validation Process (OAC-FORTA 2016)

Literature - Wehling M, Collins R, Gil VM, et al. - Drugs Aging. 2017; published online ahead of print

Main results


All DOACs and warfarin were classified as beneficial or very beneficial in older AF patients (FORTA-A or -B), underlining the overall positive assessment of the risk-benefit ratio for these drugs based on available evidence. For other VKAs (FORTA-C) regionally used in Europe, the lack of evidence should challenge current practice.


Show references

Find this article online at Drugs & Aging

Share this page with your colleagues and friends: